Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Breast Neoplasms 66Lymphoma 35Neutropenia 30Lymphoma, Large B-Cell, Diffuse 23Lymphoma, Non-Hodgkin 18Neoplasms 15Carcinoma, Non-Small-Cell Lung 14Ovarian Neoplasms 13Hodgkin Disease 13Sarcoma 11Multiple Myeloma 11Lymphoma, Mantle-Cell 10Lymphoma, Follicular 10Leukemia 10Burkitt Lymphoma 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lung Neoplasms 9Triple Negative Breast Neoplasms 8Rhabdomyosarcoma 7Leukemia, Lymphocytic, Chronic, B-Cell 7Chemotherapy-induced Neutropenia 7Central Nervous System Neoplasms 6Breast Neoplasms, Male 6Testicular Neoplasms 5Prostatic Neoplasms 5Neoplasm Metastasis 5Lymphoma, B-Cell, Marginal Zone 5Febrile Neutropenia 5Fallopian Tube Neoplasms 5Carcinoma, Ovarian Epithelial 5

Interventions

Temozolomide 11Cyclophosphamide 11Radiotherapy 7Magnetic Resonance Spectroscopy 6Filgrastim 6Cisplatin 6Vincristine 5Etoposide 5Carboplatin 5antineoplaston AS 2-1 4antineoplaston A10 4sargramostim 3Thiotepa 3Melphalan 3Carmustine 3Automobiles 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3gallium Ga 68 dotatate 2fludarabine 2dactolisib 2aldesleukin 2Thalidomide 2TH 302 2Surveys and Questionnaires 2Paclitaxel 2Irinotecan 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Gadolinium DTPA 2Everolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroectodermal Tumors, Primitive × pegfilgrastim × Clear all
NCT02943733 2022-09-23

Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs

University of Wisconsin, Madison

Phase 1 Terminated
18 enrolled
EndocrineNET

Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡